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Abstract: The interrelations between fatigue, depression and health-related quality of life (HRQoL) 
in persons with multiple sclerosis (PwMS) are complex, and the directionality of the effects is un-
clear. To address this gap, the current study used a longitudinal design to assess direct and indirect 
effects of fatigue and depression on HRQoL in a one-year follow-up survey. A sample of 210 PwMS 
from the nationwide Swiss MS Registry was used. HRQoL was assessed using the European Quality 
of Life 5-Dimension 5-Level questionnaire. Path analysis on HRQoL, with fatigue and depression as 
predictors, was applied. Fatigue was measured by the Modified Fatigue Impact Scale (MFIS), in-
cluding physical, cognitive and psychosocial subscales, and non-somatic depressive symptomatol-
ogy was examined with the Beck Depression Inventory-Fast Screen (BDI-FS). Fatigue acted as a fully 
mediating variable (B = −0.718, SE = 0.253) between non-somatic depressive symptomatology and 
HRQoL. This indirect effect became apparent in the physical (B = −0.624, SE = 0.250), psychosocial 
(B = −0.538, SE = 0.256) and cognitive subscales (B = −0.485, SE = 0.192) of fatigue. In contrast, non-
somatic depressive symptomatology did not act as a mediator. Our findings provide novel and clin-
ically relevant longitudinal evidence showing that the debilitating effect of non-somatic aspects of 
depression on HRQoL was fully mediated and therefore explainable via fatigue. 
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1. Introduction 
Health-related quality of life (HRQoL) is considerably reduced in persons with mul-
tiple sclerosis (PwMS) compared with both the general population and populations with 
other chronic diseases [1–3]. Previous research identified various clinical (e.g., fatigue, dis-
ability status, disease duration, progressive MS course and relapses in the last 3 months), 
sociodemographic (e.g., employment, sex, age, education and socioeconomic status) and 
psychological risk factors (e.g., depression, anxiety and perceived stress) that contribute 
to the impaired HRQoL in PwMS [2–6]. In this context, the negative impact on PwMS’s 
HRQoL by the two common and troublesome conditions of fatigue (affecting up to 93% 
at some point during the course of the disease [7–10]) and depression (lifetime prevalence 
20–50% [11–15]) has been demonstrated in various cross-sectional studies [16–22] and also 
in a few longitudinal studies [23,24]. However, fatigue and depression show a large 
amount of overlapping features, challenging the investigation of their effects on HRQoL 
if considered independently. Few examples in the literature have addressed this topic, 
and the relationship generally remains poorly understood [25]. Therefore, the interrela-
tion of fatigue and depression in HRQoL requires more consideration in PwMS. 
Path analysis is a statistical method that can account for such interrelated variables 
by differentiating their direct and indirect effects. So far, two studies applied path analysis 
to examine the relation between fatigue and depression on HRQoL [2,26]. The first study, 
based on a Spanish sample, showed that depression mediated the relationship between 
some HRQoL domains, such as mental health, and fatigue in PwMS [26]. It was limited 
by unexpectedly low levels of depression in almost all PwMS [26]. The second study, 
based on a large Canadian sample, demonstrated that the relation of depression on 
HRQoL was almost equally split into a direct and indirect association through its influ-
ence on fatigue or anxiety. This finding indicated that the influence of depression on 
HRQoL may be partly mediated by its effects on fatigue [2]. Because these two studies 
were cross-sectionally designed, causal conclusions were, however, limited. Longitudinal 
data would provide the possibility of examining the direction of the relations, but despite 
the importance of the issue, no study with PwMS has applied a longitudinal analysis on 
the interrelation between fatigue and depression on HRQoL up to now. 
Moreover, studies subdividing fatigue into its different cognitive and physical com-
ponents showed that the relation between depression and fatigue in PwMS was more pro-
nounced for cognitive fatigue in comparison with physical fatigue [27,28]. This finding 
suggests that specific components of fatigue should be considered, as it is a heterogeneous 
construct with somatic and non-somatic symptoms [8]. Additionally, depression is an in-
herently heterogeneous construct comprising non-somatic as well as somatic components. 
Consequently, specific instruments assessing depression under the exclusion of overlap-
ping somatic symptoms were thus developed to counteract a potentially biased overesti-
mation of depression in PwMS [29–32] (somatic symptoms: loss of energy, sleep problems, 
irritability, appetite problems, fatigue and loss of interest in sex; cognitive or affective 
symptoms: sadness, pessimism, past failure, loss of pleasure, guilty feelings, punishment 
feelings, self-dislike, self-criticism, suicidal ideation, crying, agitation, loss of interest, in-
decisiveness, worthlessness and concentration problems [33]). Therefore, it is important 
that longitudinal analyses on fatigue and depression in PwMS take into account that both 
entities have somatic and non-somatic phenomena. 
Our objective was to examine the directionality of fatigue and depression on HRQoL 
in a national database of PwMS by applying a longitudinal path analysis. First, we hy-
pothesized that the influence of depression on HRQoL would be mediated via fatigue. In 
doing so, we focused on the non-somatic aspects of depressive symptomatology in order 
to distinguish them from MS-related fatigue. Second, we hypothesized that the impact via 
the cognitive fatigue subscale on HRQoL will be more pronounced compared with the 
physical and psychosocial fatigue subscales.  
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2. Materials and Methods 
2.1. Study Sample and Data Collection 
The Swiss MS Registry (SMSR) is a patient-centered prospective study assessing the 
life circumstances of adult PwMS and their relatives and proxies in Switzerland 
(http://www.Clinical-Trials.gov, accessed on 04/06/2021, identifier: NCT02980640). This 
observational study was initiated and is funded by the Swiss MS Society, and it is based 
on self-reported data. Study recruitment started in June 2016 and is still ongoing (n = 2465, 
status quo 19 April 2021). Participation is possible via an online system or via paper-pencil 
versions, and all surveys are offered in German, French or Italian [34,35]. The SMSR was 
approved by the ethics committee of the Canton of Zurich (PB-2016-00894; BASEC-NR 
2019-01027), and the participants signed written informed consent after being informed 
about the study’s procedure and aims in writing [34]. 
In total, 563, 491 and 707 participants filled out the 18-month, 24-month and 36-
month follow-up surveys, respectively (status quo as per 8 June 2020; Figure 1). For the 
current study, we focused only on PwMS with complete data in all three follow-up sur-
veys assessing depression, fatigue and HRQoL, leading to a final subsample of n = 210. 
The reduction of the sample was mainly due to the restricted availability of the depression 
and fatigue instruments.  
 
Figure 1. Flow chart describing the study sample of the Swiss Multiple Sclerosis Registry (num-
bers reflect numbers of persons; status quo: 8 June 2020). Abbreviations: SMSR = Swiss MS Regis-
try and HRQoL = Health-related quality of life. 
2.2. Measurements 
Information on the basic sociodemographic and health-related variables was ob-
tained from the preliminary SMSR assessments (labelled as "initial" and "baseline") and 
comprised the following factors: sex, age, education level, occupational status, civil status 
and smoking status. 
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Information on HRQoL, the primary outcome, was collected twice: in the 18-month 
(t0) and 36-month follow-up surveys (t1). HRQoL was assessed using the European Qual-
ity of Life 5-Dimension 5-Level questionnaire (EQ-5D-5L). This questionnaire covered the 
following five dimensions: (1) mobility, (2) self-care, (3) usual activities, (4) pain or dis-
comfort and (5) anxiety or depression [36,37]. It provided a visual analogue scale (EQ-
VAS) and an estimation of a single utility figure (also referred to as the EQ-5D-index). For 
the current study, the French value set was used [38,39]. The EQ-VAS ranged from 0 
(worst imaginable health) to 100 (best imaginable health), and the EQ-5D-index was re-
scaled from 0 (worst health) to 100 (best health) [40]. 
The following information was taken from the 24-month follow-up survey. 
The Modified Fatigue Impact Scale (MFIS) is a modified form of the Fatigue Impact 
Scale [41] and assesses fatigue in terms of physical, cognitive and psychosocial functioning 
apart from an overall fatigue sum score. This questionnaire has been recommended for 
research purposes and in clinical practice [42]. It consists of 21 items, and individual sub-
scales can be generated by calculating the sum of a specific set of items. The MFIS has a 
Cronbach’s alpha of 0.92 [43]. Clinically relevant fatigue was based on the MFIS sum score 
cut-off greater than or equal to 38 as recommended elsewhere [43]. 
The seven-item Beck Depression Inventory-Fast Screen (BDI-FS) [44] assessing cur-
rent subjective burden resulting from depression was applied. This self-rating question-
naire has been specifically validated for use with PwMS [31]. The BDI-FS captures depres-
sion (time span: past two weeks) under the exclusion of somatic features. Thus, it coun-
teracts the potentially biased overestimation of depression prevalence in PwMS due to 
confounding with MS-related symptoms, such as fatigue. Clinically relevant non-somatic 
depressive symptomatology was defined as a BDI-FS sum score greater than or equal to 
4, as this cut-off showed sensitivity between 0.97 and 1.00 and specificity between 0.79 
and 0.99 [45,46]. 
The Expanded Disease Status Scale (EDSS) ranges from 0 to 10, with low values in-
dicating no physical disability or disturbance and high values indicating greater disabil-
ity. Information on the EDSS was derived from the self-reported disability status scale 
(SRDSS), a proxy measure based on the same cohort [47]. EDSS proxy values were dichot-
omized into high (defined as scores ≥4) versus low (defined as scores <4) disability. 
In addition, the MS disease phenotypes and the time since MS diagnosis were col-
lected in the two-year follow-up SMSR survey. MS disease phenotypes were dichoto-
mized into two groups: (1) relapsing-remitting MS (RRMS) versus (2) progressive MS 
courses (secondary progressive MS (SPMS), primary progressive MS (PPMS) and transi-
tions between MS courses). 
2.3. Statistical Analysis 
Descriptive statistics were provided by absolute and relative frequencies or medians 
(interquartile range (IQ) 25th percentile (PI); 75 PI). Univariable and multivariable associ-
ations between the depression sum scores and the fatigue sum scores as potential media-
tor (M) or suppressor (S) variables on the metric HRQoL were computed using regression 
analysis (unstandardized coefficient B, standardized coefficient β and odds ratios (ORs) 
with 95% confidence intervals (CIs)). The following criteria of Baron and Kenny were ap-
plied in order to check the variables in terms of potential Ms and if partial or full media-
tion occurred: (1) independent variable (IV) on dependent variable (DV) significant; (2) IV 
on M/S significant; (3) M/S on DV significant; and (4) a multiple regression of IV and M/S 
on DV, in which M/S remained significant and IV was either no longer significant (full 
mediation) or still significant but reduced in its strength (partial mediation) [48]. 
Statistical significance was defined as a p-value <0.05. The selection of relevant inde-
pendent variables and covariates was based on a combination of theoretical evidence and 
a backward selection of variables (p-values: in = 0.05; out = 0.10). Goodness-of-fit according 
to Cohen [49] was used for judging the overall model. 
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Separate path models with HRQoL as the DV were computed, treating (1) non-so-
matic depressive symptomatology as the IV and fatigue as M and (2) fatigue as the IV and 
non-somatic depressive symptomatology as M. An additional path model was computed, 
differentiating between the fatigue subscales. Considering that the EQ-5D-index is com-
posed of physical components, which are similarly captured by the MFIS, we used the 
EQ-VAS, assessing subjective burden as the principal outcome. Unstandardized regres-
sion coefficients (B) were computed as recommended elsewhere [50]. Indirect effects, im-
plying that an IV caused the M and the M caused the DV, were considered significant if 
the 95% CI did not contain the value 1.0 [51], based on Sobel’s method [52]. 
The path models were conducted using Mplus for Macintosh, version 8 [53]. A de-
scriptive analysis and regression analysis were performed in IBM SPSS Statistics for Mac-
intosh, version 25.0 [54] and Stata software for Macintosh, version 13.1 [55]. 
3. Results 
3.1. Descriptive Analysis 
The sociodemographic characteristics of the sample (n = 210) of PwMS living in Swit-
zerland are presented in Table 1. Participants had a mean age of 51.0 years and were pre-
dominantly female (71%), highly educated (62%), working (68%) and married or in a reg-
istered partnership (58%). In total, 70% of participants reported having an RRMS, while 
the other larger groups were composed of secondary SPMS (17%) and PPMS courses (8%). 
The mean MS disease duration was 11.0 years. A proportion of 70% had EDSS proxy val-
ues [47] of 3.5 maximum, while around 30% had higher scores, indicating higher levels of 
disability. Around a third of the sample reached the critical score level that was consid-
ered to reflect clinically relevant fatigue symptomatology, derived from the MFIS scores. 
The HRQoL scores showed medians of 80 (EQ-VAS) and 71 (EQ-5D-index) for both time 
points. Considering the BDI-FS scores, approximately a quarter of the sample fulfilled the 
criteria for a clinically significant depressive symptomatology. Missing values concerning 
potential covariates were between 0.5% and not more than 3.3% per variable (Table 1). 
Table 1. Demographic and disease-related characteristics of the Swiss MS Registry sample (n = 
210). 
Sample Characteristic n =210 
Sociodemographics  
Sex  
Women 150 (71.4%) 
Men 60 (28.6%) 
Age (median (IQR)) 50.5 (44.0; 58.0) 
Education 1, a  
Low 78 (38.2%) 
High 126 (61.8%) 
Occupational status b  
Working 141 (67.5%) 
Not working 68 (32.5%) 
Urbanicity 2  
Urban 192 (91.4%) 
Urban to rural 3 (1.4%) 
Rural 15 (7.1%) 
Civil status  
Married or registered partnership 121 (57.6%) 
Other 89 (42.4%) 
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Clinical MS-related 
MS Disease Course c 
 
CIS 2 (1.0%) 
RRMS 146 (69.9%) 
PPMS 17 (8.1%) 
SPMS 36 (17.2%) 
Transition or other type 8 (3.8%) 
Dichotomized MS Disease Course (Excluding CIS) c  
RRMS 146 (70.5%) 
Progressive MS (PPMS, SPMS, Transition) 61 (29.5%) 
Time since MS Diagnosis d (median (IQR)) 11.0 (6.0; 17.0) 
Disease Modifying Treatment e (current, past 6 months)  
Yes 146 (71.2%) 
No 59 (28.8%) 
Bouts f (current, past 6 months)  
Yes 15 (7.8%) 
No 177 (92.2%) 
Proxy Measure to Estimate EDSS g  
EDSS 0–3.5 147 (70.3%) 
EDSS 4–6.5 45 (21.5%) 
EDSS ≥ 7 17 (8.1%) 
Fatigue Sum Scores (MFIS)  
Clinically relevant fatigue 71 (33.8%) 
No clinically relevant fatigue 139 (66.2%) 
Overall sum score (median (IQR)) 30.0 (13.8;42.0) 
Cognitive subscale (median (IQR)) 11.0 (5.0;18.0) 
Physical subscale (median (IQR)) 15.0 (5.8;20.0) 
Psychosocial subscale (median (IQR)) 3.0 (1.0;4.3) 
Health-Related Quality of Life  
EQ-VAS (18-month follow-up survey) (median (IQR)) 80.0 (65.0;90.3) 
EQ-5D-index (18-month follow-up survey) h (median (IQR)) 71.1 (50.5;92.9) 
EQ-VAS (36-month follow-up survey) (median (IQR)) 80.0 (60.0;90.0) 
EQ-5D-index (36-month follow-up survey) i (median (IQR)) 71.4 (47.2;91.0) 
Clinical Depression-Related BDI-FS  
Clinically relevant depressive symptomatology 53 (25.2%) 
No clinically relevant depressive symptomatology 157 (74.8%) 
Overall sum score (median (IQR)) 1.0 (0.0;4.0) 
Antidepressants   
Yes 16 (7.6%) 
No 197 (92.9%) 
If yes (n = 16)   
Selective serotonin reuptake inhibitors (SSRIs) 5 (31.2%) 
Serotonin–norepinephrine reuptake inhibitors (SNRIs) 5 (31.2%) 
Serotonin antagonist and reuptake inhibitors (SARIs) 1 (6.3%) 
Tricyclic antidepressants (TCAs) 1 (6.3%)  
Herbal antidepressants (St. John's wort) 2 (12.5%) 
Detailed information missing 2 (12.5%) 
Psychotherapy  
Yes 32 (15.2%) 
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No 178 (84.8%) 
Consumption of Psychoactive Substances  
Smoking Status   
Still smoking 35 (16.7%) 
No 175 (83.3%) 
Results are shown as a number (percentage) or median (range or interquartile range (25PI; 75PI)). 
Abbreviations: MS = multiple sclerosis; IQR = interquartile range; CIS = clinically isolated syn-
drome; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS; PPMS = primary pro-
gressive MS; EDSS = Expanded Disease Status Scale; MFIS = Modified Fatigue Impact Scale; EQ-
5D = the European Quality of Life-5 Dimensions; FU = follow-up; and BDI-FS = Beck Depression 
Inventory-Fast Screen for medical patients. 1 High: High school or higher. 2 Based on the Federal 
Statistical Office of Switzerland. a n = 6; b n = 1; c n = 1; d n = 7; e n = 5; f n = 18; g n = 1; h n = 1; i n = 1. 
3.2. Regression and Path Analysis 
Table 2 provides the univariable and multivariable associations of the first mediation 
model, using depression as the IV and fatigue as M, which met the criteria according to 
Baron and Kenny. On the one hand, high BDI-FS depression scores (IV) were significantly 
associated with higher MFIS fatigue sum scores (M) and, on the other hand, reduced EQ-
VAS HRQoL scores (DV). Reduced EQ-VAS scores were also significantly associated with 
high MFIS fatigue sum scores (M). However, as soon as both the IV and M were inserted 
into the model, the effect of the IV on the DV failed to reach significance, while the effect 
of M on the DV remained significant. These results indicated a full mediation of the IV on 
the DV via the M variable, according to the Baron and Kenny criteria (Table 2). Based on 
the backward selection of variables, all analyses were adjusted for EQ-VAS at t0, sex, age, 
civil status, EDSS proxy values and MS disease courses. The R2 for the overall model was 
0.53 (adjusted = 0.51), indicating high goodness-of-fit according to Cohen [49]. On the con-
trary, the Baron and Kenny criteria were not fulfilled in the second mediation model, 
where the MFIS fatigue sum score was set as the IV variable and the BDI-FS depression 
scores were the M variable, thus suggesting that the association between fatigue and 
HRQoL was not explainable via depression (data not shown). 
Table 2. Univariable and multivariable results of the variables meeting the mediator criteria according to Baron and Kenny 
(1986) [48], adjusted 1 (n = 206) 2. 
    Effects on EQ-5D (DV) 
IV M 
Effect of IV on M 
Direct Effect of IV on 
DV 
Effect of M on DV 
Effect of IV on DV after Inclu-
sion of M to the Model 
Estimate Estimate Estimate Estimate 








1.926 0.326 0.345 <0.001 −0.828 0.378 −0.125 0.030 −0.265 0.075 −0.224 <0.001 −0.373 0.402 −0.056 0.355 
BDI-FS = Beck Depression Inventory-Fast Screen for medical patients; MFIS = Modified Fatigue Impact Scale; IV = inde-
pendent variable; M = mediator; DV = dependent variable; B = unstandardized coefficient; SE = standard error; β = stand-
ardized coefficient; EQ-5D = the European Quality of Life-5 Dimensions; and EDSS = Expanded Disease Status Scale. 1Ad-
justed for EQ-VAS (t0) sex, age, civil status EDSS proxy values and MS disease course. 2 From the original sample of n = 
210, 4 (1.9%) persons were excluded due to missing values on the covariates, leading to a final sample of n = 206. Bold 
indicates p < 0.05 significance level. 
Figure 2 presents the unstandardized parameter estimates of the first path model, 
including the overall MFIS fatigue sum score. The estimates indicated a full mediation of 
the BDI-FS depression scores on EQ-VAS HRQoL scores via the MFIS fatigue sum scores, 
showing that the effect of non-somatic depressive symptomatology on HRQoL was split 
into a non-significant direct path (B = −0.373, SE = 0.393) and a significant indirect path (B 
= −0.718, SE = 0.253) via fatigue. 
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Figure 2. Path analysis of the psychological predictors of depression and fatigue for health-related 
quality of life (EQ-VAS) in persons with MS (n = 206). The values on the arrows are unstandard-
ized parameter estimates with standard errors. Bold indicates significance (p < 0.05). Abbrevia-
tions: IV = independent variable; DV = dependent variable; M = mediator; CV = covariates; MS = 
multiple sclerosis; BDI-FS = Beck Depression Inventory-Fast Screen; MFIS = Modified Fatigue Im-
pact Scale; HRQoL = health-related quality of life; EQ-VAS = European Quality of Life 5-Dimen-
sion 5-Level version visual analogue scale; and EDSS = Expanded Disease Status Scale. 
The indirect effects from three separate path models differentiated by the MFIS fa-
tigue subscales of physical, cognitive and psychosocial functioning are presented in Table 
3. The physical subscale (B = −0.624, SE = 0.250) and the psychosocial subscale (B = −0.538, 
SE = 0.256) showed the strongest indirect effects between the BDI-FS depression scores 
and a reduced EQ-VAS HRQoL, whereas the effect via the cognitive subscale was slightly 
weaker (B = −0.485, SE = 0.192). However, all three indirect effects were significant. 
Table 3. Indirect effects by fatigue subscales, derived from three separate path analyses of the pre-
dictors depression and fatigue, on health-related quality of life (EQ-VAS) in persons with MS (n = 
206) 1. 
MFIS Subscale B SE 
Physical subscale −0.624 0.250 
Psychosocial subscale −0.538 0.256 
Cognitive subscale −0.485 0.192 
B = unstandardized coefficient and SE = standard error. 1Adjusted for EQ-VAS (t0), sex, age, civil 
status, MS disease course (dichotomized) and EDSS proxy values. Bold indicates p < 0.05 signifi-
cance level. Abbreviations: MFIS = Modified Fatigue Impact Scale; EQ-VAS = European Quality of 
Life 5-Dimension 5-Level version visual analogue scale; and EDSS = Expanded Disease Status 
Scale. 
4. Discussion 
Our longitudinal results suggest that fatigue fully mediates the association between 
non-somatic depressive symptomatology and HRQoL in PwMS. This indirect mediation 
effect on HRQoL became apparent in all three fatigue subscales, with the most severe im-
pact occurring in the physical and psychosocial fatigue subscales followed by the cogni-
tive fatigue subscale. Therefore, the debilitating influence of the non-somatic aspect of 
depression on HRQoL was explained by indirect effects exerted by fatigue. 
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The finding of the indirect effect between depression and HRQoL through fatigue 
supports our first hypothesis, predicting that the influence of depression on HRQoL 
would be mediated by fatigue. So far, two cross-sectional studies previously considered 
the interrelation between fatigue and depression on HRQoL by path analysis. Our find-
ings were in accordance with a Canadian study based on a large sample of PwMS report-
ing the same relation [2]. Moreover, we were able to substantiate the evidence by adopting 
a longitudinal approach, which is more suitable than cross-sectional analyses when hy-
pothesizing causal relationships between IVs and DVs and applying path analysis mod-
els. Notably, by capturing the non-somatic aspects of depression (i.e., referring to the cog-
nitive and affective dimensions), we avoided a potential overestimation bias, which inev-
itably appears when including somatic depression features in PwMS [32]. Hence, this dif-
ferent way of assessing depression may also explain why we detected a full mediation, in 
contrast to the aforementioned Canadian study showing partial mediation [2]. Finally, the 
differentiation by the three fatigue subscales was also a new clinically relevant aspect of 
the current study. 
In contrast, the path analysis study based on a Spanish sample had an inversed the-
oretical framework by hypothesizing that the effect of an HRQoL domain (mental health) 
on fatigue was mediated by depression in PwMS [26]. This was explained by the fact that 
PwMS with fatigue experience decreased cognitive function, promoting depressive symp-
toms which are followed again by increased self-perceived fatigue, pointing to a vicious 
cycle [26,56]. The etiology of fatigue in MS is not precisely understood and is thought to 
be heterogeneous, with different underlying pathophysiological mechanisms leading to 
the same downstream symptomatology [8]. While some authors see fatigue as a direct 
consequence of the MS disease process itself (e.g., [57]), others interpret it as a corollary 
effect of depression or sleep disturbances (e.g., [30]). A study directly comparing four 
models predicting fatigue in PwMS highlighted depression and sleep disturbances as 
strong predictors of fatigue, apart from disease severity [58]. Therefore, our hypothesis 
that the disabling nature of non-somatic depressive symptomatology may contribute to 
fatigue in PwMS seems highly plausible, even though it is possible that it is restricted 
mainly to the secondary aspect of fatigue [59]. 
In addition, studies not applying longitudinal path analysis reported worse HRQoL 
for PwMS with depression or fatigue (e.g., [3,17,21,23,24]). In line with these studies, we 
previously showed in a cross-sectional analysis that depression belonged to the three lead-
ing symptoms for HRQoL losses in persons with RRMS courses [16]. In addition, our pre-
sent study confirmed the detrimental effect of depression on HRQoL for the non-somatic 
depressive symptomatology. 
The strength of the relationship between depression and fatigue was more pro-
nounced for cognitive fatigue in comparison with physical fatigue in PwMS in previous 
research [27,28]. A cytokine-mediated pathogenesis of depression and cognitive fatigue 
was suggested as a possible explanation for this relation [27]. However, we were not able 
to identify a differential relationship of any fatigue subscale regarding non-somatic de-
pressive symptomatology and the HRQoL outcome. In fact, all three fatigue subscales 
were statistically associated with HRQoL, even though the most severe impact occurred 
in the physical and psychosocial fatigue subscales, followed by the cognitive subscale. 
Thus, our second hypothesis, predicting the strongest impact via the cognitive fatigue 
subscale on HRQoL, was not supported. This finding may reflect the intricate multifacto-
rial relationship between the physical, as well as cognitive, and psychosocial components, 
whose interaction transposes then into an inextricable main effect. In fact, up regulated 
inflammatory activity, which may lead to depressive symptomatology by altering neu-
roinflammatory as well as monoamine and glutaminergic metabolism pathways in the 
brain, occurred in response to psychosocial as well as cognitive and physical stressors or 
pathogens [60]. 
Our study contributes to a better directional understanding of the overlapping and 
heterogeneous constructs of fatigue and depression on HRQoL in PwMS by considering 
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their specific components and by disentangling their direct and indirect effects in a longi-
tudinal design. From a clinical point of view, the overlap of depression and fatigue in 
PwMS depicts a particular therapeutic challenge [61]. Hence, it is of clinical importance to 
differentiate between the somatic components of depression that may appear to be pre-
ponderant due to their MS-related physical symptomatology and some subtle non-so-
matic signs indicating mental affliction. By doing so, disadvantageous pharmacological 
interventions based on the overinterpretation of somatic signs (e.g., “drug-induced low-
mood”) can be avoided. Hence, for these overlapping cases, Brenner and Piehl [61] sug-
gested that it is prudent to first treat depressive symptoms before fatigue due to the better 
evidence for pharmacological interventions in depression. An alternative therapeutic av-
enue for reducing fatigue in PwMS that is gaining increasing attention is the use of con-
templative techniques, such as mindfulness-based interventions. These have shown po-
tential for treating fatigue in MS [62–64] and have the additional benefit that specific pro-
grams exist that focus on depression (e.g., mindfulness-based cognitive therapy (MBCT) 
[65]). 
Limitations 
Our study has some limitations that warrant discussion. We adopted a statistical ap-
proach based on particular mediation criteria concerning the relations of depression, fa-
tigue and HRQoL, even though these criteria earned some criticism [66] and additional 
interactions and causal relations between these variables may occur. Additionally, both 
variants (1) that fatigue may include depression, but (2) it can also occur independently 
[58] are certainly plausible. Thus, our approach does not mirror the entire heterogeneity; 
rather, it reflects one possible occurrence of the overlapping constructs of depression and 
fatigue, partly referring to secondary fatigue. When interpreting the results, it is also im-
portant to consider that fatigue is a broad construct with some facets that are also present 
in non-somatic depressive symptomatology. Therefore, one might have anticipated that 
the non-somatic form of depression may be more probable to be represented in fatigue 
than vice versa in the tested path model relations. Nevertheless, non-somatic depressive 
symptomatology was not only reflected in the cognitive fatigue component but also in the 
physical and psychosocial one, which did not confirm this assumption. Moreover, we can-
not exclude the possibility that the physical fatigue subscale at least in part contains the 
commonly captured somatic aspects of depression. A similar difficulty pertains to the un-
avoidable overlap of both the concepts of depression and HRQoL. This overlap may result 
in poorer judgment of the HRQoL, depending on the level of depression severity as was 
discussed by other authors [30]. Assessing the HRQoL following the remission of depres-
sion or rated by other persons are possibilities for avoiding this kind of negative bias be-
tween depression and HRQoL [30]. However, we judged this bias as marginal for the cur-
rent study, as different time frames between depression screening and HRQoL assessment 
were applied. In addition, the EQ-VAS captures the current daily condition, which can 
vary. Considering the highly stable EQ-VAS medians between the two separate surveys, 
however, this is not a serious limitation. Another limitation of the study is that the t0-
HRQoL was assessed six months before the BDI-FS and MFIS. Therefore, we cannot ex-
clude that further factors occurring in the time span might have contributed to some t1-
HRQoL shifts. Moreover, antidepressant and fatigue treatments were not included in the 
final path analysis. The interrelations of this variable with depression, fatigue and HRQoL 
are ambiguous, complex and would require separate path analyses. However, the effects 
found in the current study remained stable under the inclusion of antidepressant treat-
ment as an additional covariate in an exploratory manner. Then, sleep disturbances and 
cognitive dysfunction were not considered in the current analysis, despite their relation-
ship with both fatigue and depression [58]. We only focused on the two particularly trou-
blesome factors of fatigue and depression, although many other causal pathways predict-
ing HRQoL in PwMS are possible. Additionally, generalizability might be limited, as the 
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included subsample with complete data on depression, fatigue and HRQoL led to an un-
avoidable selection bias with older, highly educated, often-employed participants with 
rather good physical functioning. Finally, the novel clinically relevant entity referring to 
“long COVID syndrome” was not yet ongoing in the data collection used for the current 
analysis, but it needs special attention in future studies. 
5. Conclusions 
The current study provides novel longitudinal evidence by demonstrating that the 
impact of non-somatic depressive symptomatology on HRQoL was explainable by an in-
direct effect via fatigue. Here, all fatigue subscales (physical, psychosocial and cognitive 
fatigue) mediated this relation. Although this study focused on how the effect of depres-
sion on HRQoL is mediated by fatigue, it is important to keep in mind that fatigue in 
PwMS can occur independently of depression. For PwMS with both depression and fa-
tigue, it is of clinical importance that pharmacological and non-pharmacological interven-
tions are appropriately considered regarding both conditions. For example, pharmacolog-
ical treatment of underlying depression and mindfulness-based interventions may have a 
positive effect not only on depression but also on fatigue. In particular, regarding physical 
and psychosocial fatigue, which is reflected in difficulty participating in social or outdoor 
activities, non-pharmacological interventions such as the enhancement of physical activ-
ity might be feasible and potentially promising. A better understanding of the underlying 
mechanisms of the interrelations between depression, fatigue and HRQoL is needed and 
should be targeted in future research. 
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